Publications by authors named "W Bensinger"
Background: The increasing use of anti-CD38 monoclonal antibodies (αCD38 mAbs) for newly diagnosed or early relapsed multiple myeloma (MM), especially in non-transplant eligible patients, may lead to more patients developing αCD38 mAb-refractory disease earlier in the treatment course with fewer treatment options.
Patients And Methods: We analyzed the efficacy and safety of selinexor-based triplets (selinexor+dexamethasone [Sd] plus pomalidomide [SPd, n = 23], bortezomib [SVd, n = 16] or carfilzomib (SKd, n = 23]) in a subset of STOMP (NCT02343042) and BOSTON (NCT03110562) study patients treated previously with αCD38 mAbs.
Results: Sixty-two patients (median 4 prior therapies, range 1 to 11, 90.
Article Synopsis
- * Data from 11 heavily pretreated patients indicate that selinexor (X) regimens show strong effectiveness and produce lasting responses, even when used later in treatment.
- * X-containing regimens resulted in better overall response rates and longer progression-free survival compared to previous anti-BCMA treatments, highlighting their potential in addressing an ongoing treatment gap.
In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of LYRA (median months of follow-up: NDMM, 35.7; RMM, 35.
View Article and Find Full Text PDFArticle Synopsis
- Proteasome inhibitors, such as carfilzomib, enhance the effectiveness of selinexor, a new oral treatment, in battling multiple myeloma (MM) based on preclinical studies.
- A clinical trial involving 32 patients assessed the safety, maximum-tolerated dose (MTD), and efficacy of selinexor combined with carfilzomib and dexamethasone, finding significant adverse effects but manageable under supportive care.
- The combination treatment led to an impressive 78% overall response rate, with a median progression-free survival of 15 months, indicating that weekly XKd is both effective and well-tolerated for relapsed refractory MM patients.
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma patients. Isatuximab (10 mg/kg weekly for 4 weeks, then every other week) was administered as a fixed-volume infusion of 250 mL (mL/h infusion rate) with standard doses of Pd on 28-day cycles.
View Article and Find Full Text PDF